MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Clinical trials for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New tests could transform care for rare kidney diseases
Knowledge-focused OngoingThis study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers to find markers t…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: NA • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC